Giannelli G - Search Results

1

Proteolytic balance in patients with multiple sclerosis during interferon treatment.

Giannelli G, De Marzo A, Scagnolari C, Bergamini C, Fransvea E, Bagnato F, Bellomi F, Millefiorini E, Gasperini C, Antonaci S, Antonelli G. Giannelli G, et al. J Interferon Cytokine Res. 2002 Jun;22(6):689-92. doi: 10.1089/10799900260100187. J Interferon Cytokine Res. 2002. PMID: 12162880

2

Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN.

Milella M, Antonelli G, Santantonio T, Giannelli G, Currenti M, Monno L, Turriziani O, Pastore G, Dianzani F. Milella M, et al. Among authors: giannelli g. Hepatogastroenterology. 1995 Jul;42(3):201-4. Hepatogastroenterology. 1995. PMID: 7590565

3

Clinical significance of recombinant interferon-alpha 2 neutralizing antibodies in hepatitis patients.

Antonelli G, Giannelli G, Pistello M, Maggi F, Vatteroni L, Currenti M, Del Vecchio S, Roffi L, Pastore G, Dianzani F. Antonelli G, et al. Among authors: giannelli g. J Interferon Res. 1994 Aug;14(4):211-3. doi: 10.1089/jir.1994.14.211. J Interferon Res. 1994. PMID: 7822878 Clinical Trial. No abstract available.

4

Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-alpha) during therapy for chronic hepatitis C.

Giannelli G, Antonelli G, Fera G, Del Vecchio S, Riva E, Broccia C, Schiraldi O, Dianzani F. Giannelli G, et al. Clin Exp Immunol. 1994 Jul;97(1):4-9. doi: 10.1111/j.1365-2249.1994.tb06571.x. Clin Exp Immunol. 1994. PMID: 8033418 Free PMC article.

5

2',5'-Oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C.

Giannelli G, Antonelli G, Fera G, Dianzani F, Schiraldi O. Giannelli G, et al. J Interferon Res. 1993 Feb;13(1):57-60. doi: 10.1089/jir.1993.13.57. J Interferon Res. 1993. PMID: 8454912

6

Effects of interferon-alpha treatment on neutrophil oxidative metabolism, lymphocyte proliferation and monocyte HLA class I antigen expression in patients with chronic hepatitis C.

Piazzolla G, Giannelli G, Antonelli G, Tortorella C, Jirillo E, Schiraldi O, Antonaci S. Piazzolla G, et al. Among authors: giannelli g. Immunopharmacol Immunotoxicol. 1996 Nov;18(4):529-48. doi: 10.3109/08923979609052752. Immunopharmacol Immunotoxicol. 1996. PMID: 8933168

7

Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha2 therapy.

Antonelli G, Giannelli G, Currenti M, Simeoni E, Del Vecchio S, Maggi F, Pistello M, Roffi L, Pastore G, Chemello L, Dianzani F. Antonelli G, et al. Among authors: giannelli g. Clin Exp Immunol. 1996 Jun;104(3):384-7. doi: 10.1046/j.1365-2249.1996.43747.x. Clin Exp Immunol. 1996. PMID: 9099919 Free PMC article.

8

Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion.

Giannelli G, Bergamini C, Fransvea E, Marinosci F, Quaranta V, Antonaci S. Giannelli G, et al. Lab Invest. 2001 Apr;81(4):613-27. doi: 10.1038/labinvest.3780270. Lab Invest. 2001. PMID: 11304581 Free article.

9

Biological and clinical relevance of Laminin-5 in cancer.

Giannelli G, Antonaci S. Giannelli G, et al. Clin Exp Metastasis. 2000;18(6):439-43. doi: 10.1023/a:1011879900554. Clin Exp Metastasis. 2000. PMID: 11592300 Review.

10

Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma.

Giannelli G, Bergamini C, Marinosci F, Fransvea E, Quaranta M, Lupo L, Schiraldi O, Antonaci S. Giannelli G, et al. Int J Cancer. 2002 Feb 1;97(4):425-31. doi: 10.1002/ijc.1635. Int J Cancer. 2002. PMID: 11802202

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

401 results

Search Page

Filters